Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...
BMY Beats Analyst Estimates
Bristol Myers Squibb reported strong third-quarter financial results, notching an 18% jump in its growth portfolio.
Bristol-Myers Squibb Company (NYSE:BMY) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...
Global Oncology Pharmaceuticals Market: Revolutionizing Cancer Care Worldwide
PRNewswire/ -- "According to the latest BCC research study, the demand for Global Oncology Pharmaceuticals Market increased ...
India becoming part of global drug development operation of BMS: Samit Hirawat
Right now India doesn’t allow first-in-human trials for drug products discovered outside ... We’re not there yet. Oncology, ...
Bristol Myers Squibb Posts Robust Q3 2024 Growth
Bristol-Myers Squibb Company ( (BMY) ) has released its Q3 earnings. Here is a breakdown of the information Bristol-Myers Squibb Company ...
Investing7d
Bristol-Myers Squibb's SWOT analysis: stock faces headwinds amid pipeline progress
As other key products in BMY's portfolio approach ... What potential does BMY's oncology pipeline have for future growth? Bristol-Myers Squibb's oncology pipeline remains a key area of focus ...
FiercePharma4d
Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
Seeking Alpha11d
Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
Good day, and welcome to the Bristol-Myers Squibb Third Quarter 2024 Earnings ... During the quarter, we saw solid demand for key products across our growth and legacy portfolios.